EXHIBIT A
U.S. Application No. 09/328,296
Pennie & Edmonds LLP Docket No. 9632-005
Marked up Versions of Replacement Paragraphs

Marked up version of replacement Table of Contents section on page ii, line 19:

Marked up version of replacement paragraph for paragraph on pages 24-25 beginning "For preparation of additional monoclonal antibodies to CD40":

For preparation of additional monoclonal antibodies to CD40, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique of Kohler and Milstein, (1975, Nature 256, 495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kozbor *et al.*, 1983, Immunology Today 4, 72; Cole *et al.*, 1983, Proc. Natl. Acad. Sci. USA 80, 2026-2030), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies or other anti-CD40 antibodies available in the art may, e.g., be used as the basis from which to clone and thus supply a complementary light chain if a S2C6 heavy chain is to be recombinantly expressed (the two chains may be recombinantly expressed in the same cell or combined in vitro after separate expression and purification); alternatively, a light chain from an antibody of any specificity may be used. Nucleic acids (e.g., a plasmid) encoding a S2C6 heavy chain or encoding a molecule comprising a S2C6 heavy chain variable domain can be transfected into a cell expressing an antibody light chain or molecule comprising an antibody light chain, for expression of a multimeric protein; the antibody light chain can be recombinant or non-recombinant, and may or may not have anti-CD40 specificity. Alternatively, S2C6 heavy chains or molecules comprising the variable region thereof or a CDR thereof can optionally be expressed and used without the presence of a complementary light chain or light chain variable region. In various embodiments, the invention provides a S2C6 heavy chain with CD40 binding affinity, or a molecule consisting of or (alternatively) comprising one or more copies of heavy chain CDR 1, 2, and/or 3 (corresponding to SEQ ID NO:8, 9, and/or 10, respectively), or a protein (peptide or

polypeptide) the sequence of which consists of, or comprises, one or more copies of CDR 1, 2 or 3 (corresponding to SEQ ID NO:8, 9 or 10, respectively). In a specific embodiment, such a protein can be N or C-terminal modified, e.g., by C-terminal amidation or N-terminal acetylation.

Marked up version of replacement paragraph header for the paragraph header on page 58 entitled "10. DEPOSIT OF MICROORGANISM":

10. DEPOSIT OF [MICROORGANISM] HYBRIDOMA